Table 1.
Comparison of major characteristics according to hospitalization in intensive care unit (ICU) or not for adult patients with incident candidemia due to common species (YEASTS program, Paris area, October 2002 to September 2010)
| Conditions | Hospitalization wards, n (%) | |||
|---|---|---|---|---|
| ICU (N = 1,206) | Outside ICU (N = 1,301) | p | ||
| Male gender | 748 (62.0 %) | 763 (58.7 %) | 0.0844 | |
| Age categories | ||||
| <45 years | 219 (18.2 %) | 241 (18.5 %) | 0.9320 | |
| 45–64 years | 469 (38.9 %) | 499 (38.4 %) | ||
| 65–79 years | 384 (31.8 %) | 407 (31.3 %) | ||
| ≥80 years | 134 (11.1 %) | 154 (11.9 %) | ||
| Age mean ± SD | 60 ± 17 | 60 ± 17 | 0.7482 | |
| Central venous catheter | 936 (77.6 %) | 919 (70.6 %) | <0.0001 | |
| Arterial catheter | 401 (33.3 %) | 40 (3.1 %) | <0.0001 | |
| Surgery within 30 days | 580 (48.1 %) | 389 (29.9 %) | <0.0001 | |
| Digestive tracta | 262/580 (45.2 %) | 190/389 (48.8 %) | <0.0001 | |
| Cardiovascular | 120/580 (20.7 %) | 20/389 (5.1 %) | ||
| Orthopedic | 45/580 (7.8 %) | 56/389 (14.4 %) | ||
| Urinary tract | 23/580 (3.4 %) | 46/389 (11.8 %) | ||
| Gynecologic | 7/580 (1.2 %) | 12/389 (3.1 %) | ||
| Neurosurgery | 13/580 (2.4 %) | 5/389 (1.3 %) | ||
| Unspecified/other sites | 71/580 (12.2 %) | 40/389 (10.3 %) | ||
| Multiple sitesb | 39/580 (6.7 %) | 20/389 (5.1 %) | ||
| Malignancy | ||||
| No malignancy | 828 (68.7 %) | 418 (32.1 %) | <0.0001 | |
| Hematological malignancy | 137 (11.4 %) | 285 (21.9 %) | ||
| Solid tumor | 241 (20.0 %) | 598 (46.0 %) | ||
| Solid organ transplantation | 127 (10.5 %) | 35 (2.7 %) | <0.0001 | |
| HIV infection | 51 (4.3 %) | 47 (3.8 %) | 0.4372 | |
| Allo HSCT/BMT | 18 (1.5 %) | 28 (2.2 %) | 0.2189 | |
| Intravenous drug addiction | 9 (0.75 %) | 17 (1.3 %) | 0.1664 | |
| Previous antifungal treatment | ||||
| All | 128 (10.6 %) | 109 (8.4 %) | 0.0559 | |
| Fluconazole | 79 (6.6 %) | 56 (4.3 %) | 0.0127 | |
| Caspofungin | 25 (2.1 %) | 28 (2.2 %) | 0.8904 | |
| Type of infection | ||||
| Single pathogen | ||||
| C. albicans | 668/1169 (57.1 %) | 689/1255 (54.9 %) | 0.2664 | 0.0167 |
| C. glabrata | 234/1,169 (20.0 %) | 216/1,255 (17.2 %) | 0.0758 | |
| C. parapsilosis | 106/1,169 (9.1 %) | 173/1,255 (13.8 %) | 0.0003 | |
| C. tropicalis | 106/1,169 (9.1 %) | 119/1,255 (9.5 %) | 0.7253 | |
| C. krusei | 35/1,169 (3.0 %) | 35/1,255 (2.8 %) | 0.7631 | |
| C. kefyr | 20/1,169 (1.7 %) | 23/1,255 (1.8 %) | 0.8204 | |
| Multiple pathogens | 37 (3.1 %) | 46 (3.5 %) | 0.5131 | |
| First-line treatment after diagnosisb | ||||
| Fluconazole | 506/914 (55.4 %) | 665/1,111 (59.9 %) | 0.0415 | 0.0013 |
| Echinocandins | 239/914 (26.2 %) | 212/1,111 (19.1 %) | 0.0001 | |
| Others (including combination) | 115/914 (12.6 %) | 148/1,111 (13.3 %) | 0.6224 | |
| No treatment | 54/914 (5.9 %) | 86/1,111 (7.7 %) | 0.1057 | |
| Death rate | ||||
| Overall death at day 30 | 591/1,158 (51.0 %) | 371/1,210 (30.7 %) | <0.0001 | |
| Before day 8 | 367/1,151 (31.9 %) | 182/1,204 (15.1 %) | <0.0001 | |
| Proportional mortality day 8/day 30 | 367/584 (62.8 %) | 182/365 (49.9 %) | <0.0001 | |
| Between days 8 and 30 | 217/1,151 (18.9 %) | 183/1,204 (15.2 %) | 0.0183 | |
| Proportional mortality day 8–30/day 30 | 217/584 (37.2 %) | 183/365 (50.1 %) | <0.0001 | |
Data are mean ± SD or n/N (%) —denominator is specified when missing data
HSCT hematopoietic stem cell transplant, BMT bone marrow transplantation
aDigestive tract surgery includes gastroesophageal, hepatobiliary, colorectal, and pancreatic surgical procedures
bDenominator represents the number of patients for whom the positivity of the blood culture was known before death and/or for whom the information about treatment was recorded